Figure 1.
LLC1 is resistant to immune checkpoint blockades, while ASB-XIV is sensitive. (A) BALB/c (n = 5) and C57BL/6 mice (n = 6) were subcutaneously inoculated with 1 × 106 cells of ASB-XIV and LLC1 lung cancer cells, respectively. Then, mice received anti-PD-1 (200 μg), anti-CTLA-4 mAb (100 μg), or a combination of both treatments. Anti-PD-1 was administered on days 3, 6, and 9. Anti-CTLA-4 mAb was administered on days 0, 4, and 8. (B) Tumor-infiltrating immune cells in ASB-XIV and LLC1 tumors (n = 4) were analyzed by flow cytometry on days 7, 14, and 21. (C) RNA expression of LLC1 tumors (n = 3) was evaluated on days 7, 14, and 21. The composition of tumor-infiltrating immune cells was evaluated by mMCP-counter. * p < 0.05, ** p < 0.01, *** p < 0.001.